Artificial Intelligence in Drug Discovery Market - Global Forecast 2026-2032
Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Artificial Intelligence in Drug Discovery Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The Artificial Intelligence in Drug Discovery Market research report examines a sector projected to reach USD 3.03 billion in 2026 and grow at a CAGR of 23.07% to USD 10.66 billion by 2032. It assesses how AI is becoming a core R&D capability across target identification, hit discovery, lead optimization, ADMET prediction, biomarker discovery, and clinical trial design.
Market Transformation and Growth Drivers
AI adoption is supported by major scientific and technological advances, including the AlphaFold Protein Structure Database with more than 200 million predicted protein structures, the U.S. FDA's work on AI and machine learning in drug development, and wider access to high-performance cloud computing.
Generative AI, graph neural networks, natural language processing, and multimodal foundation models enable researchers to analyze chemical libraries, omics datasets, protein structures, publications, patents, and real-world data at scale. The report provides strategic context for prioritizing investments, evaluating technology partnerships, and identifying high-value applications.
Impact on Drug Research and Development
AI-enabled platforms support earlier, evidence-driven decisions by identifying disease-relevant targets, screening virtual compound libraries, forecasting toxicity, optimizing molecular properties, and improving patient stratification. Their primary value lies in shortening hypothesis cycles, reducing avoidable experimentation, and prioritizing candidates before costly laboratory or clinical investments.
AI does not eliminate uncertainty associated with complex biology, safety, efficacy, manufacturability, or clinical execution. Sustainable competitive advantage depends on combining proprietary data, laboratory validation, model governance, and cross-functional expertise across biology, chemistry, informatics, clinical development, and regulatory affairs.
Regulatory and Operational Considerations
Regulators, including the U.S. FDA and EMA, are increasing their focus on model transparency, validation, data provenance, and risk management. Cloud infrastructure, secure collaboration, and automation are also enabling teams to evaluate more hypotheses while maintaining traceability and reproducibility.
These insights support risk mitigation by highlighting the governance, cybersecurity, documentation, and validation capabilities required for responsible deployment.
Regional Market Insights
North America: Leads through its concentration of pharmaceutical companies, AI-native biotechnology firms, academic medical centers, cloud providers, venture capital, and regulatory engagement. The United States remains the most influential market, while Canada contributes advanced machine learning expertise.
Europe: Combines strong biomedical research and manufacturing with regulatory modernization through initiatives such as the EU AI Act and European Health Data Space. The United Kingdom, Germany, France, Italy, and Spain offer significant research, manufacturing, clinical trial, and translational medicine capabilities.
Asia-Pacific: China, India, Japan, South Korea, Singapore, and Australia are expanding investments in genomics, precision medicine, computational biology, clinical research, and biomanufacturing.
Latin America, Middle East, and Africa: Brazil and Mexico offer clinical research and pharmaceutical manufacturing foundations. The UAE and Saudi Arabia are advancing genomics and precision medicine, while Africa presents opportunities linked to genomic diversity, infectious disease research, biobanks, and improved model generalizability.
Country and regional comparisons provide a practical basis for market entry planning, partnership selection, and geographic expansion.
Strategic Group Insights
The EU is emerging as a reference market for trustworthy life sciences AI, while G7 countries continue to shape standards through R&D intensity and regulatory coordination. BRICS markets offer population scale, manufacturing capacity, and expanding clinical networks. ASEAN and GCC countries are advancing through digital health, biomedical investment, and population genomics, while NATO members influence biosecurity, cybersecurity, resilient supply chains, and trusted data infrastructure.
Actionable Recommendations
Industry leaders should prioritize measurable use cases such as target validation, virtual screening, toxicity prediction, protein structure analysis, biomarker discovery, and trial enrichment.
. Build proprietary, interoperable datasets and robust data architectures.
. Establish model validation, bias monitoring, cybersecurity, and regulatory documentation.
. Embed computational scientists alongside chemists, biologists, clinicians, and regulatory experts.
. Structure partnerships around data rights, auditability, privacy, model ownership, and milestone-based outcomes.
Key Takeaways from This Report
. The market is forecast to grow from USD 3.03 billion in 2026 to USD 10.66 billion by 2032.
. AI is becoming integral to multiple stages of drug discovery and development.
. Proprietary data, scientific validation, and disciplined governance are critical differentiators.
. North America leads adoption, while Europe and Asia-Pacific are developing strong innovation ecosystems.
. Effective human-AI operating models remain essential for converting computational insights into therapeutic progress.
Key Attributes:
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Artificial Intelligence in Drug Discovery Market, by Offering
7.1. Introduction
7.2. Software Platforms
7.3. Discovery Services
8. Artificial Intelligence in Drug Discovery Market, by Discovery Workflow
8.1. Introduction
8.2. Hit Identification & Screening
8.3. Hit-to-Lead & Lead Optimization
8.4. Target Identification & Validation
8.5. Preclinical Candidate Assessment
9. Artificial Intelligence in Drug Discovery Market, by Therapeutic Modality
9.1. Introduction
9.2. Small-Molecule Therapeutics
9.3. Protein & Peptide Therapeutics
9.4. Nucleic-Acid Therapeutics
9.5. Combination & Conjugate Therapeutics
9.6. Cell-Based Therapeutics
10. Artificial Intelligence in Drug Discovery Market, by Data Foundation
10.1. Introduction
10.2. Chemical & Molecular Structure Data
10.3. Omics & Biological Sequence Data
10.4. Biomedical Text & Knowledge Graph Data
10.5. Imaging & Phenotypic Data
10.6. Clinical & Real-World Data
10.7. Integrated Multimodal Data
11. Artificial Intelligence in Drug Discovery Market, by End User
11.1. Introduction
11.2. Pharmaceutical & Biotechnology Companies
11.3. Contract Research & Development Organizations
11.4. Academic, Government & Nonprofit Research Institutions
12. Artificial Intelligence in Drug Discovery Market, by Region
12.1. Introduction
12.2. North America
12.3. Europe
12.4. Asia-Pacific
12.5. Latin America
12.6. Middle East
12.7. Africa
13. Artificial Intelligence in Drug Discovery Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. European Union
13.5. BRICS
13.6. ASEAN
13.7. GCC
14. Artificial Intelligence in Drug Discovery Market, by Country
14.1. Introduction
14.2. United States
14.3. China
14.4. United Kingdom
14.5. Japan
14.6. Germany
14.7. Canada
14.8. France
14.9. India
14.10. Australia
14.11. South Korea
14.12. Brazil
14.13. Italy
14.14. Mexico
14.15. Spain
14.16. Russia
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Schrodinger, Inc.
16.2. Certara, Inc.
16.3. Dassault Systemes SE
16.4. Insilico Medicine Cayman TopCo
16.5. Charles River Laboratories International, Inc.
16.6. Recursion Pharmaceuticals, Inc.
16.7. XtalPi Holdings Limited
16.8. Isomorphic Labs
16.9. NVIDIA Corporation
16.10. insitro
16.11. Valo Health, LLC
16.12. Causaly Ltd
16.13. Owkin Inc.
16.14. Genesis Molecular AI
16.15. AbCellera Biologics Inc.
16.16. Generate Biomedicines, Inc.
16.17. Aqemia
16.18. BenevolentAI
16.19. Iambic Therapeutics, Inc.
16.20. Iktos
16.21. Immunai Inc.
16.22. SandboxAQ
16.23. Terray Therapeutics, Inc.
16.24. Verge Analytics, Inc.
16.25. Atomwise Inc.
16.26. Deep Genomics Incorporated
16.27. Standigm
16.28. Pathos AI, Inc.
16.29. Relation Therapeutics Limited
16.30. Healx Ltd.
16.31. Enveda Therapeutics, Inc.
16.32. EvolutionaryScale
16.33. Chai Discovery, Inc.
16.34. Xaira Therapeutics, Inc.
16.35. Absci Corporation
16.36. Lantern Pharma Inc.
17. Key Experts
For more information about this report visit https://www.researchandmarkets.com/r/2p0vt4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.